Meta-analysis of the Efficacy and Safety of Edaravone Dexborneol in the Treatment of Cerebral Infarction
DOI:
https://doi.org/10.54097/e47kch87Keywords:
Edaravone Dexborneol, Cerebral Infarction, Meta-analysisAbstract
The purpose is to evaluate the efficacy and safety of edaravone dexborneol in treating cerebral infarction. Methods: Computer searches were conducted on databases such as PubMed, Cochrane Library, and Web of Science to identify randomized controlled trials of edaravone dexborneol in treating cerebral infarction. Meta-analysis was performed by Review Manager 5.4.1 software on eligible studies. Results: A total of 10 studies meeting the inclusion criteria were included, with a total of 3,324 patients. The Meta-analysis showed that compared to the control group, edaravone dexborneol significantly improved total effective rate, enhanced excellent functional outcomes, and reduced IL-6 levels, with statistically significant differences; however, there were no statistically significant differences in neurological function improvement compared to the control group; in terms of reducing adverse reactions, the control group had a more favorable outcome than edaravone dexborneol, with statistically significant differences. Conclusion: Edaravone dexborneol can significantly improve clinical outcomes in treating cerebral infarction, but may increase the incidence of adverse reactions. Therefore, it is necessary to select appropriate treatment regimens based on clinical circumstances to achieve optimal clinical outcomes.
Downloads
References
[1] Fu Y, Wang A, Tang R, Fu Y, Wang A, Tang R, et al. Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke: The TASTE-SL Randomized Clinical Trial. JAMA Neurol. 2024 Feb 19;81(4):319–26.
[2] Li Y, Liu J, Zhu Y, Li Y, Liu J, Zhu Y, et al. Effects of butylphthalide sodium chloride injection combined with edaravone dexborneol on neurological function and serum inflammatory factor levels in sufferers having acute progressive cerebral infarction. Front Neurol. 2024 Dec 19; 15:1415977.
[3] Mi Y, Hou Z, Liu J, Mi Y, Hou Z, Liu J, et al. Clinical study of Edaravone Dexborneol combined with Tirofiban in treatment of Acute Cerebral Infarction. Pak J Med Sci. 2024 Jan-Feb;40(1Part-I):190-194.
[4] Xu M, Li L, Xu B, et al. Observations on the efficacy of edaravone dexborneol in preventing post-stroke depression and its inflammatory mechanism: a prospective, randomized, control trial. Front Neurosci. 2024 Sep 9; 18:1451060.
[5] Zhang XL, Liu Y, Cheng X, Zhang XL, Liu Y, Cheng X, et al. Effect of edaravone dexborneol on the serum levels of lipoprotein-related phospholipase A2 and high-sensitivity C-reactive protein in patients with acute cerebral infarction. Asian J Surg. 2023 Mar;46(3):1420-1421.
[6] Hu X, Qian Z, Chen J, Hu X, Qian Z, Chen J, et al. Effects of edaravone dexborneol on neurological function and serum inflammatory factor levels in patients with acute anterior circulation large vessel occlusion stroke. Transl Neurosci. 2023 Oct 12;14(1):20220312.
[7] Xu J, Wang A, Meng X, et al. TASTE Trial Investigators. Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial. Stroke. 2021 Mar;52(3):772-780.
[8] Xu J, Wang Y, Wang A, Xu J, Wang Y, Wang A, et al. Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial. Stroke Vasc Neurol. 2019 Apr 22; 4(3):109-114.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

